SOURCE-LINKED STUDY SUMMARY
Advances in oral peptide therapeutics.
Abstract summarizedQuality not appraised
- What was studied
- This review described barriers to oral peptide delivery and strategies including permeation enhancers, gut-enzyme inhibitors, and mucus- or cell-penetrating peptides.
- Who / model studied
- It discussed clinical-trial experience with oral insulin, calcitonin, parathyroid hormone, vasopressin, and semaglutide; the abstract reported no single population, sample size, or follow-up period.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The review highlighted oral semaglutide's approval for type 2 diabetes as a landmark advance, while emphasizing that gastrointestinal structure and physiology remain substantial delivery barriers.
- Limitations & context
- This was a broad review rather than a comparative intervention trial, and the abstract did not provide quantitative efficacy or safety outcomes.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41573-019-0053-0